Tevogen Bio Holdings Inc. (NASDAQ: TVGN) has filed an S-3 registration statement covering the resale of 375,000 shares of common stock issuable upon exercise of pre-funded warrants held by a single entity: The Patel Family LLP, a vehicle linked to founder and CEO Dr. Manmohan Patel.
The warrants carry an exercise price of $0.0001 per share — effectively zero — meaning the shares are issuable for negligible additional consideration. They were issued as part of a May 2026 private placement that raised approximately $3.0 million, implying a cost basis of roughly $8.00 per share for the holder. At the time of filing, TVGN's market price was approximately $11.67.
Float and Dilution Mechanics
The 375,000 registered shares represent approximately 9% of the company's 4.22 million shares currently outstanding. Because the warrants are pre-funded, the capital has already been received by the company; exercise would not generate meaningful new proceeds. Once the registration statement is declared effective, the shares could be freely resold into the public market at the holder's discretion.
A 9.99% beneficial ownership blocker is embedded in the warrant terms, which caps the number of shares The Patel Family LLP can hold at any given time. This mechanism limits the pace at which warrants can be exercised and shares can enter the float, but it does not limit the total number that can ultimately be converted — it simply gates the timing.
Structural Concentration Worth Noting
What distinguishes this filing is the density of convertible instruments concentrated in the hands of a single related party. Beyond the pre-funded warrants covered by this S-3, The Patel Family LLP holds interests across multiple layers of the capital structure, including Series A preferred stock, Series A-1 preferred stock, Series C preferred stock, and an interest-in-stock loan arrangement. Each of these instruments carries its own conversion mechanics and potential claims on common equity.
This layered insider convertible stack means that the 375,000 shares in the current filing represent only one tranche of potential dilution from a single holder. The aggregate dilutive capacity across all instruments held by the Patel-linked entities is materially larger than what this individual registration covers.
Filing Structure
The S-3 is a resale shelf — not an at-the-market (ATM) offering and not a primary issuance. The company itself is not selling shares or raising capital through this registration. Rather, it is fulfilling a registration obligation to The Patel Family LLP, likely a contractual term of the May 2026 PIPE.
Because the pre-funded warrants have no meaningful exercise price floor, the shares are convertible regardless of where the stock trades. There is no price-based protection mechanism that would prevent exercise during periods of declining share value. The 9.99% blocker remains the only structural constraint on the rate of conversion and subsequent resale.